NASDAQ: TARS - Tarsus Pharmaceuticals, Inc.

Yield per half year: +27.28%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Tarsus Pharmaceuticals, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc., биофармацевтическая компания на клинической стадии, специализируется на разработке и коммерциализации новых терапевтических кандидатов для офтальмологических состояний. Его ведущим кандидатом в продукт является TP-03, новый терапевтический препарат, который находится в фазе IIb / III для лечения блефарита, вызванного заражением клещами Demodex, а также для лечения болезни мейбомиевых желез. Компания также разрабатывает TP-04 для лечения купероза; и TP-05 для профилактики Лайма и снижения заболеваемости малярией. Tarsus Pharmaceuticals, Inc.

more details
была зарегистрирована в 2016 году, ее штаб-квартира находится в Ирвине, Калифорния.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2020-10-16
ISIN US87650L1035
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт http://www.tarsusrx.com
Цена ао 50.78
Change price per day: +5.24% (44.12)
Change price per week: -1.25% (47.02)
Change price per month: -1.42% (47.1)
Change price per 3 month: -11.88% (52.69)
Change price per half year: +27.28% (36.48)
Change price per year: +28.37% (36.17)
Change price per 3 year: +150.3% (18.55)
Change price per year to date: -12.82% (53.26)
All parameters

Underestimation

Title Value Grade
P/S 33.95 1
P/BV 3.01 5
P/E 0 0
EV/EBITDA -2.81 0
Total: 4

Efficiency

Title Value Grade
ROA, % -51.04 0
ROE, % -68.99 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.2124 10
Total: 9.6

Growth impulse

Title Value Grade
Yield Revenue, % -47.76 0
Yield Ebitda, % 3276.15 10
Yield EPS, % 133.58 10
Total: 8
More

Institutions Volume Share, %
RTW Investments LP 3152341 9.21
Blackrock Inc. 2516139 7.35
Cormorant Asset Management, LP 2221422 6.49
Tang Capital Management, LLC 2204797 6.44
Morgan Stanley 1957688 5.72
COWEN AND COMPANY, LLC 1911399 5.59
Frazier Life Sciences Management, L.P. 1787527 5.22
Vivo Capital, LLC 1784006 5.21
Vanguard Group Inc 1595501 4.66
Perceptive Advisors LLC 1296416 3.79

ETFShare, %Profitability for 1 year, %Dividends, %
Future Tech ETF 0.12645 426.34 0.8416
Principal Healthcare Innovators ETF 0.12645 618.5 0.8416
iShares Morningstar Small-Cap Growth ETF 0.02659 596.94 0.72598
iShares Morningstar Small-Cap ETF 0.01793 391.25 1.60498
iShares Morningstar Small-Cap Value ETF 0.00907 197.28 2.50476
0.06446.061.3



Head Job title Payment Year of birth
Dr. Bobak R. Azamian M.D. Co-Founder, President, CEO & Chairman 962.08k
Dr. Seshadri Neervannan Ph.D. Chief Operating Officer 486.67k 1968 (57 years)
Dr. Bryan Wahl J.D., M.D. General Counsel & Corporate Secretary 619.09k 1978 (47 years)
Mr. David Nakasone Head of Investor Relations N/A
Mr. Matthew Rossen M.B.A. Vice President of Marketing N/A 1978 (47 years)
Dr. Elizabeth Yeu Lin M.D. Chief Medical Advisor & Director 286k 1978 (47 years)
Ms. Adrienne Kemp Senior Director of Corporate Communications N/A
Mr. Jeffrey S. Farrow CFO & Chief Strategy Officer N/A 1962 (63 years)
Mr. Scott Youmans Vice President of Sales N/A
Ms. Dianne C. Whitfield M.S.W. Chief Human Resources Officer 578.9k 1977 (48 years)

Address: United States, Irvine, 15440 Laguna Canyon Road - open in Google maps, open in Yandex maps
Website: http://www.tarsusrx.com